OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 04:01 UTC. Every row links to its source record.

RAD51D RAD51 paralog D

ENSG00000185379 · protein coding · Open Targets profile

Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Bind to single-stranded DNA (ssDNA) and has DNA-dependent ATPase activity. Part of the RAD51 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 acts downstream of BRCA2 recruitment and upstream of RAD51 recruitment. BCDX2 binds predominantly to the intersection of the four duplex arms of the Holliday junction and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. Involved in telomere maintenance. The BCDX2 subcomplex XRCC2:RAD51D can stimulate Holliday junction resolution by BLM. {ECO:0000269|PubMed:10871607, ECO:0000269|PubMed:11751635, ECO:0000269|PubMed:11834724, ECO:0000269|PubMed:11842113, ECO:0000269|PubMed:12975363, ECO:0000269|PubMed:15109494, ECO:0000269|PubMed:23149936}.

In 12 of 15 cancers, the evidence for RAD51D comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751hereditary breast ovarian cancer syndro…hereditary breast ovarian cancer syndromehereditary breast ovarian cancer syndrome: germline 0.87ovarian cancerovarian cancerovarian cancer: somatic 0.43ovarian cancer: germline 0.82ovarian carcinomaovarian carcinomaovarian carcinoma: germline 0.73RAD51D-related cancer predispositionRAD51D-related cancer predispositionRAD51D-related cancer predisposition: germline 0.82hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95ovarian neoplasmovarian neoplasmovarian neoplasm: somatic 0.43ovarian neoplasm: germline 0.82gastric cancergastric cancergastric cancer: germline 0.86familial ovarian cancerfamilial ovarian cancerfamilial ovarian cancer: germline 0.87breast cancerbreast cancerbreast cancer: germline 0.82breast-ovarian cancer, familial, suscep…breast-ovarian cancer, familial, susceptibility to, 1breast-ovarian cancer, familial, susceptibility to, 1: germline 0.73hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.70breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.55prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.8623499870300293 (upper bound 1.1303000450134277). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of RAD51D's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of RAD51D's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.